Wells Fargo & Company upgraded shares of Sunesis Pharmaceuticals (NASDAQ:SNSS) from a market perform rating to an outperform rating in a research report released on Monday morning, MarketBeat reports. Wells Fargo & Company currently has $2.48 price target on the biopharmaceutical company’s stock, down from their previous price target of $2.86.

Other analysts have also issued research reports about the stock. Cantor Fitzgerald set a $3.00 price target on shares of Sunesis Pharmaceuticals and gave the stock a hold rating in a research note on Tuesday, December 5th. Oppenheimer assumed coverage on shares of Sunesis Pharmaceuticals in a research note on Tuesday, November 21st. They issued an outperform rating and a $7.00 price target for the company. UBS assumed coverage on shares of Sunesis Pharmaceuticals in a research note on Monday, November 20th. They issued an outperform rating for the company. Zacks Investment Research lowered shares of Sunesis Pharmaceuticals from a buy rating to a hold rating in a research note on Wednesday, October 4th. Finally, Cowen restated a hold rating on shares of Sunesis Pharmaceuticals in a research note on Thursday, November 2nd. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and three have given a buy rating to the stock. The stock currently has an average rating of Hold and a consensus price target of $3.75.

Shares of Sunesis Pharmaceuticals (NASDAQ SNSS) opened at $3.34 on Monday. Sunesis Pharmaceuticals has a 12 month low of $1.82 and a 12 month high of $4.45. The company has a current ratio of 1.84, a quick ratio of 1.84 and a debt-to-equity ratio of -0.34.

Sunesis Pharmaceuticals (NASDAQ:SNSS) last posted its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported ($0.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.06). During the same quarter in the prior year, the firm posted ($0.62) EPS. equities research analysts forecast that Sunesis Pharmaceuticals will post -1.58 earnings per share for the current year.

In other news, Director Dayton Misfeldt purchased 400,000 shares of Sunesis Pharmaceuticals stock in a transaction dated Friday, October 27th. The stock was bought at an average price of $2.00 per share, with a total value of $800,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Mpm Oncology Impact Management purchased 25,300 shares of Sunesis Pharmaceuticals stock in a transaction dated Thursday, November 2nd. The shares were purchased at an average cost of $2.59 per share, with a total value of $65,527.00. The disclosure for this purchase can be found here. In the last quarter, insiders have acquired 506,800 shares of company stock valued at $1,091,282. 10.21% of the stock is owned by insiders.

Institutional investors and hedge funds have recently made changes to their positions in the company. Wells Fargo & Company MN boosted its holdings in shares of Sunesis Pharmaceuticals by 77.4% during the second quarter. Wells Fargo & Company MN now owns 41,851 shares of the biopharmaceutical company’s stock valued at $113,000 after acquiring an additional 18,254 shares during the period. Virtu KCG Holdings LLC acquired a new position in shares of Sunesis Pharmaceuticals during the second quarter valued at $208,000. Renaissance Technologies LLC boosted its holdings in shares of Sunesis Pharmaceuticals by 1.1% during the first quarter. Renaissance Technologies LLC now owns 111,811 shares of the biopharmaceutical company’s stock valued at $458,000 after acquiring an additional 1,230 shares during the period. Sphera Funds Management LTD. boosted its holdings in shares of Sunesis Pharmaceuticals by 54.6% during the second quarter. Sphera Funds Management LTD. now owns 193,212 shares of the biopharmaceutical company’s stock valued at $522,000 after acquiring an additional 68,212 shares during the period. Finally, Vanguard Group Inc. boosted its holdings in shares of Sunesis Pharmaceuticals by 4.1% during the second quarter. Vanguard Group Inc. now owns 605,759 shares of the biopharmaceutical company’s stock valued at $1,635,000 after acquiring an additional 23,819 shares during the period. 38.43% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: This story was originally posted by Watch List News and is the sole property of of Watch List News. If you are accessing this story on another publication, it was illegally stolen and republished in violation of U.S. and international copyright legislation. The correct version of this story can be read at https://www.watchlistnews.com/sunesis-pharmaceuticals-snss-upgraded-at-wells-fargo-company/1762865.html.

Sunesis Pharmaceuticals Company Profile

Sunesis Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Company offers QINPREZO (vosaroxin), which is a product candidate for the treatment of acute myeloid leukemia (AML).

Receive News & Ratings for Sunesis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunesis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.